BFLY vs SYRE
Butterfly Network, Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | BFLY | SYRE |
| AI Score |
67
|
67
|
| Price |
$9.36
|
$102.72
|
| P/E Ratio |
-32.38×
|
-52.69×
|
| ROE |
-39.3%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
0.0%
|
| Debt / Equity |
0.10×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.4
|
53.3
|
| Beta |
2.084
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus SYRE.
The committee scores are tied.
BFLY and SYRE both score 67/100.
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical